论文部分内容阅读
目的探讨骨肽联合降钙素治疗原发性骨质疏松症的临床疗效。方法选择76例经门诊补钙止痛等治疗无效的原发性骨质疏松症入院患者,每日给予骨肽粉针50 mg静脉滴注及肌内注射鲑鱼降钙素50 U治疗,2周为一疗程。结果经治疗一疗程后,对治疗前及治疗后VAS及治疗结果进行统计,VAS评分下降5分以上49例(64.5%),下降3~4分17例(22.4%),下降1~2分8例(10.5%),下降0分2例(2.6%),其中治愈16例(21.1%),显效37例(48.7%),有效21例(27.6%),无效2例(2.6%)。结论骨肽联合降钙素治疗,能明显减轻原发性骨质疏松患者的疼痛,改善生活质量。
Objective To investigate the clinical efficacy of osteopeptide and calcitonin in the treatment of primary osteoporosis. Methods Sixty-76 patients with primary osteoporosis who were refractory to clinically treated calcium and analgesia were enrolled. Patients were given bone peptide injection 50 mg daily and intramuscular salmon calcitonin 50 U daily for 2 weeks A course of treatment. Results After treatment for one course of treatment, the VAS and treatment outcome before and after treatment were statistically decreased. VAS score decreased by 5 points or more in 49 cases (64.5%), decreased by 3 to 4 points in 17 cases (22.4%), decreased by 1 to 2 points There were 16 cases (21.1%) were cured, 37 (48.7%) were effective, 21 (27.6%) were effective and 2 (2.6%) were ineffective in 8 cases (10.5%). Conclusion The combination of osteopeptide and calcitonin can significantly reduce the pain and improve the quality of life in patients with primary osteoporosis.